Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/13887
ชื่อเรื่อง: Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles
ผู้แต่ง: Chittasupho C.
Lirdprapamongkol K.
Kewsuwan P.
Sarisuta N.
Keywords: chemokine receptor CXCR4
chemokine receptor CXCR4 antagonist
doxorubicin
polyglactin
antineoplastic antibiotic
chemokine receptor CXCR4
CXCR4 protein, human
doxorubicin
lactic acid
nanoparticle
polyglycolic acid
polylactic acid-polyglycolic acid copolymer
A549 cell line
Article
binding affinity
cancer cell
cell viability
controlled drug release
controlled study
drug conjugation
drug delivery system
fluorescence microscopy
fluorescence spectroscopy
human
human cell
in vitro study
light scattering
lung cancer
nanoencapsulation
particle size
protein expression
reversed phase high performance liquid chromatography
sustained drug release
zeta potential
antagonists and inhibitors
chemistry
lung tumor
metabolism
pathology
tumor cell line
Antibiotics, Antineoplastic
Cell Line, Tumor
Doxorubicin
Humans
Lactic Acid
Lung Neoplasms
Microscopy, Fluorescence
Nanoparticles
Polyglycolic Acid
Receptors, CXCR4
วันที่เผยแพร่: 2014
บทคัดย่อ: Doxorubicin is used to treat a variety of cancers, but dose limiting toxicity or intrinsic and acquired resistance limits its application in many types of cancer. CXCR4 is a chemokine receptor which implicates in metastasis of cancers including lung cancer. LFC131, a peptide inhibitor of CXCR4-ligand binding, is a linear type of low molecular weight CXCR4 antagonist. In this study, we investigated the possibility of using LFC131 conjugated nanoparticles for targeted delivering doxorubicin to CXCR4 expressing lung cancer cells. The LFC131 peptide was conjugated to sodium carboxylmethyl cellulose coated poly(dl-lactic-co-glycolic acid) (PLGA) nanoparticles. Binding and cellular uptake of doxorubicin-loaded LFC131 conjugated nanoparticles (LFC131-DOX NP) in adenocarcinomic human alveolar basal epithelial cells called A549 cells were higher and faster than that of untargeted nanoparticles. The specificity of CXCR4-mediated internalization of LFC131-DOX NPs was confirmed by using free LFC131 peptide or anti-CXCR4 monoclonal antibody. Cell studies suggested that sustained release of doxorubicin afforded by PLGA nanoparticles may enable LFC131-DOX NP as a targeted and controlled release drug delivery system. © 2014 Elsevier B.V. All rights reserved.
URI: https://ir.swu.ac.th/jspui/handle/123456789/13887
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84908373348&doi=10.1016%2fj.ejpb.2014.06.020&partnerID=40&md5=ab4de4b34a1adf81889748a8fd80ba9b
ISSN: 9396411
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.